Captopril |
||
|
Basel, 30 January 2004 Novartis Pharma AG announced it has filed an application to various regulatory authorities for a new indication for Diovan valsartan ; to improve survival and reduce cardiovascular events in patients at high-risk after surviv ing a heart attack. The application ha s been submitted in the U and in Europe to the Reference Member State, S Sweden, as part of the Mutual Recognition Procedure, to the United Kingdom and Switzerland. Further filings are planned to other health authorities including France, Australia, Asia n and Latin American countries during the next few weeks. Already approved for the first-line treatment of high blood pressure in more than 80 countries and for heart failure in more than 40 countries, Diovan is the fastest-growing branded high blood pressure treatment and also the second largest selling antihypertensive in the world. The new filing is based on the positive results of VALIANT VALsartan In Acute myocardial iNfarcTion ; , the largest long-term study ever conducted in people who have survived a heart attack. VALIANT demonstrated that Diovan prolongs survival after a heart attack as effectively as the ACE inhibitor captopril, an accepted standard of treatment, and is at least as effective as captopril in reducing recurrent heart attacks and hospitalisations for heart failure in these patients. Diovan is the only cardiovascular agent ever demonstrated by a head-to-head trial to have all the proven benefits of an ACE inhibitor, captopril, in patients following a heart attack. VALIANT adds to the cumulative evidence for the positive effects of Diovan in cardiovascular disease across key standard of care measures of powerful blood pressure lowering efficacy, proven cardioprotective benefits, excellent tolerability and superior persistency and compliance. VALIANT demonstrated that Diovan preserved 99.6% of the benefit of captopril, meaning it may reduce death to the same degree as the proven treatment. This finding translates into the potential of Diovan for a 25% reduction in premature death in patients at high risk following a heart attack. It is estimated that Diovan could potentially save 15 000-20 000 new lives in the EU and 30 000 new lives in North America each year. A rigorous head-to-head comparison of Diovan against captopril, VALIANT studied 14 703 patients at the highest risk for death following a heart attack myocardial infarction ; for an average of two years. VALIANT also studied the effects of combination treatment with Diovan and captopril in these patients. An active-control trial, VALIANT compared Diovan to a proven treatment instead of a placebo or sugar pill. VALIANT was designed and statistically powered to prove whether the effects of Diovan on all-cause mortality were comparable to captopril. Its patient population and dosing regimen were intentionally modelled after studies which established the benefits of ACE inhibitors vs. placebo so that a statistical comparison imputed placebo analysis ; could be made of their findings. No added benefits were seen with combination treatment. VALIANT demonstrates that Diovan is well-tolerated in post-heart attack patients. In VALIANT, discontinuations due to adverse events were lowest in the valsartan group and highest in the combination group. Hypotension and renal side effects were limited in number and most common in the group that received both medications together than in either group receiving valsartan or captopril alone. The rate of hypotension and renal dysfunction was.
Captopril Consumer Medicine Information What is in this leaflet Read this leaflet carefully before taking Capoten. This leaflet answers some common questions about Capoten. It does not contain all the available information. Some of the information it contains may not apply to you. It does not take the place of talking to your doctor or pharmacist. Always follow the instructions that your doctor and pharmacist give you about Capoten. Ifyou have any concerns about taking Capoten, ask your doctor or pharmacist. Keep this leaflet with the medicine. You may need to read it again What Capoten is used for Capoten is used for treating high blood pressure hypertension ; , certain heart conditions, and certain kidney conditions associated with diabetes. These are long term chronic diseases ; so it is important that you continue to take your Capoten every day. Capoten contains captopril. Aptopril belongs to a class of medicines known as ACE inhibitors. ACE inhibitors work to lower your blood pressure to normal levels if it is too high. Capoten also acts to help your heart or kidneys to work better. Your doctor will tell you why you need to take Capoten. Never let anyone else take your medicine. There is no evidence that Capoten is addictive or habit forming. Capoten is only available only with a doctor's prescription. Capoten is not recommended for use in children as there have been not enough studies of its effects in children. However it may be necessary for a child with hypertension and kidney problems to take Capoten, if this is the case your doctor will discuss all the possible risks and benefits to the child before starting therapy. Before you take Capoten When you must not take Capoten you must not take Capoten if you are pregnant or may become pregnant medical conditions know as idiopathic angioedema or hereditary angioedema you must not take Capoten if you have ever had an allergy to Capoten or any of the ingredients listed at the end of this leaflet, or to another ACE inhibitor Symptoms of an allergic reation to Capoten may include shortness of breath, wheezing or difficulty breathing swelling of the face, lips, mouth, tongue or throat which may cause difficulty breathing or swelling of any other parts of the body rash, itching or hives on the skin.
Are allergic to altace, benazepril lotensin ; , captopril.
Fig. 5. Inhibition of binding of LDL to Lp[a] and apo[a] by proline, lysine analogs, nicotinic acid, and captopril. FITC-LDL 2 g ml ; was incubated with immobilized Lp[a] top panel ; and immobilized apo[a] bottom panel ; in the presence of various concentrations 0500 mm ; of tranexamic acid ; , -ACA ; , l-proline ; , nicotinic acid ; , and captopril ; for 1 h at Bound LDL was determined as described in Materials and Methods. Values are means of three determinations for each experiment. Results are expressed as percent inhibition of LDL binding compared to the control binding measured in the absence of inhibitors. Close window pharmacy clinical policy bulletins aetna medicare prescription drug plan subject: angiotensin converting enzyme inhibitors combinations status - altace® ramipril ; x benazepril x benazepril hydrochlorothiazide hctz ; captopril x captopril hctz enalapril x enalapril hctz fosinopril x fosinopril hctz lisinopril x lisinopril hctz quinapril x quinaretic x accupril® quinapril ; x x x accuretic® quinapril hctz ; x x aceon® perindopril ; x x x capoten® captopril ; x x x capozide® captopril hctz ; x x lotensin hct® benazepril hctz ; x x lotensin® benazepril ; x x x mavik® trandolapril ; x x x monopril hct® fosinopril hctz ; x x monopril® fosinopril ; x x x prinivil® lisinopril ; x x x prinzide® lisinopril hctz ; x x uniretic® moexipril hctz ; x x x univasc® moexipril ; x x x vaseretic® enalapril hctz ; x x vasotec® enalapril ; x x x zestorectic® lisinopril hctz ; x x zestril® lisinopril ; x x x - & reg; & trade; sm & nbsp; & reg; & trade; sm ; & reg; & trade; sm x x x policy: precertification criteria under some plans, including plans that use an open or closed formulary, angiotensin-converting enzyme inhibitors accupril, aceon, altace, benazepril , capoten, captopril, enalapril, fosinopril, lisinopril , lotensin, mavik, monopril, prinivil, quinapril , univasc, vasotec, and zestril are subject to precertification. Methods: human keratinocyte cells were treated with 15 mmol l-1 captopril or with pemphigus serum and diltiazem. Reiss, Klin. Thorax- K., Herzzentrum Nordrhein-Westfalen, Georgstr. 11, 32545 Bad Oeynhausen, Germany] - Z. KARDIOL. 2003 92 11 ; - summ in ENGL, GERM Patients in whom cardiogenic shock develops after acute myocardial infarction have a very high death rate despite early reperfusion therapy. Often hemodynamic stabilization can be achieved only by implantation of a mechanical circulatory support system. When pharmacological therapy and onset of percutaneous assist devices fails in cases representing expansive myocardial impairment without any chance of recovery, the indication for implanting a total artificial heart is given. We report on our first experiences with this extensive and innovative management of irreversible cardiogenic shock patients. In five patients male, mean age 50 years ; the CardioWest total artificial heart was implanted. All patients were in irreversible cardiogenic shock despite maximal dosages of catecholamines, intraaortic balloon pump and or femorofemoral bypass. In all patients early reperfusion therapy was performed. After implantation of the CardioWest system, rapid recovery of all dysfunctional organ systems occurred in all patients. Four of five patients underwent successful heart transplantation after a mean support time of 156 days. One patient died because of enterocolic necroses caused by embolic event after termination of dicumarol therapy. In summary, first experiences justify this extensive management in these young patients who otherwise would have died within a few hours. 535. Enhanced in vitro maturation of subcultivated fetal human hepatocytes in three dimensional culture using poly-L-lactic acid scaffolds in the presence of oncostatin M - Hanada S., Kayano H., Jiang J. et al. [Dr. S. Hanada, Sakai Lab, 4th Dept., Institute of Industrial Science, University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan] - INT. J. ARTIF. ORGANS 2003 26 10 ; - summ in ENGL Fetal human liver cell fractions, which contain large numbers of hepatocyte progenitors, have high proliferation potential in vitro. To create an engineered liver tissue equivalent of a clinically significant size, however, repeated subcultivation and functional maturation are necessary in vitro. A commercially available human fetal liver cell fraction that was cultivated for some time in vitro has been reported to lose liver specific functions almost completely. We therefore investigated the effects of oncostatin M OSM ; and hepatocyte growth factor HGF ; in long term three-dimensional 3D ; culture using macroporous poly-L-lactic acid PLLA ; scaffolds on the restoration of such liver-specific functions of the fraction. 3D culture using PLLA scaffolds with OSM remarkably enhanced the albufrtin production and cytochrome P450 1A1 2 capacity with the culture time. HGF alone had no preferable effect on these functions even in 3D culture, a-fetoprotein production was consistently suppressed in the 3D culture compared with that in monolayers. This suppression was not observed in the same types of culture of hepatocarcinoma Hep G2 cells. Despite these favorable observations on the 3D culture with OSM, the final attained functional levels at the 5th week were still over ten-times lower than those of Hep G2 cells when standardized with a cellular DNA amount. Although further improvement is needed for the complete functional restoration and maturation in vitro, these results demonstrate that a combination of 3D culture using PLLA scaffolds and OSM offers promising culture conditions for in vitro maturation of human hepatocyte progenitors. 536. Aortic root replacement with a new stentless aortic valve xenograft conduit: Preliminary hemodynamic and clinical results - Carrel T.P., Berdat P., Englberger L. et al. [Dr. T. Carrel, Clinic for Cardiovascular Surgery, University Hospital Berne, CH-3010 Berne, Switzerland] - J. HEART VALVE DIS. 2003 12 6 ; summ in ENGL Background and aim of the study: Beside aortic valve-sparing surgery, a composite graft, homograft or more rarely ; an autograft are the most common options to replace a diseased or destroyed aortic root in adults. Recently, a new stentless xenograft valved conduit ShelhighTM, No-React ; was introduced in Europe. This totally biologic conduit is glutaraldehyde cross-linked, detoxified and heparin-treated with No-React, this process eliminates residual glutaraldehyde and ensures stable tissue cross-linking. The initial clinical and hemodynamic results with this porcine valved conduit in the aortic position are presented herein. Methods: Among 308 102. Currently, the first generic applicant to file an ANDA containing a paragraph IV certification is awarded 180 days of marketing exclusivity, during which the FDA may not approve a subsequent generic applicant's ANDA for the same drug product. The period of exclusivity commences from either the date of the first commercial marketing of the generic drug product or the date of a court decision declaring the patent invalid or not infringed. This exclusivity was intended to increase the economic incentives for a generic company to challenge branded manufacturers' patents. However, if the 180-day exclusivity for the first generic applicant does not run, then it could effectively preclude entry by any later ANDA filers. The FTC has challenged two interim settlements and one final settlement in connection with this provision. The agency alleged that, in each such settlement, the brand-name company paid the first generic applicant not to enter the market, preventing the running of the initial 180-day exclusivity and precluding FDA from approving any eligible subsequent generic applicants. The Study drew no conclusions about whether the settlement agreements it had reviewed were procompetitive or anti-competitive. The Study nevertheless expressed concern that brand-name companies and first generics applicants can still reach agreements that have the potential to "park" the first generic applicant's 180-day exclusivity for some period of time. Relying on its enforcement "history, " the agency recommended that copies of and doxazosin, for example, effects of captopril. Kojsova S1, Jendekova L1, Paulis L2, Csizmadiova Z1, Pechanova O1 1 Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovakia, 2 Department of Pathophysiology, Medical Faculty, Comenius University, Bratislava, Slovakia We analyzed the effects of different antihypertensive agents, thiazide-like diuretic indapamide ; and angiotensin-converting enzyme inhibitor captopril ; on the development of spontaneous hypertension. Particularly, the combine effect of these agents was studied. Six-week-old male SHR were treated with indapamide 1 mg kg day ; or captopril 10 mg kg day ; or indapamide captopril combination. After 6-week treatment, nitric oxide synthase NOS ; activity, eNOS protein expression and concentration of conjugated dienes CD ; , one of the reactive oxygen species marker, were determined in the left ventricle, aorta and kidney. Indapamide I ; , captopril C ; and indapamide captopril combination I C ; significantly decreased systolic blood pressure in young SHR I: 157 4, C: 137 2, I C: 121 1 mmHg ; in comparison with untreated rats 171 1 mmHg ; . In contrast to captopril, indapamide increased NOS activity in the aorta by 60% and attenuated concentration of CD in the kidney by 30%. Indapamide captopril combined treatment increased NOS activity and eNOS expression in the aorta and decreased CD concentration in the kidney comparably to indapamide alone treated group. In conclusion, indapamide treatment along with ACE inhibitor captopril had the additive effect on the prevention of blood pressure increase in young SHR. On the other hand, this combination increased NOS activity in the aorta similarly as indapamide alone. Thus, indapamide is responsible for NOS activity increase after the combined treatment with indapamide and captopril. This effect of indapamide may contribute to its vasorelaxant and antihypertensive properties. Supported by VEGA 2 6148 26 and 1 3429 06. Captopril and diabetes mellitusFINANCIAL STATEMENT 2001 Total expenditure rose from DKK 178.4 million to DKK 214.3 million, primarily due to the new practice of paying rent for our buildings. The rental costs of DKK 30.5 million are cancelled out by rental income of DKK 31.5 million. Research costs fell by DKK 3.9 million to DKK 85.8 million. The reduction is in the grant-funded area, which had extraordinarily high expenses in 2000 due to a change in accounting principles. Thus the reduction in costs does not represent a reduction in research activities. Research income derives from several financial sources. The table "Revenues for research work" shows that the bulk of income derives from the state appropriation for basic research. Research revenues have risen from DKK 82.6 million to DKK 98.0 million, or an increase of DKK 15.4 million. Again the increase is tied to the change in accounting principles adopted in 2000, which resulted in extraordinarily low revenues for that year. The increase in the basic government ap. Charles R. Rardin, MD Assistant Professor Brown Medical School Center for Women's Surgery Women and Infants' Hospital Providence, RI and catapres. These data suggest that ACE-I may have a role in early management as well as in the convalescence phase of acute MI but only in high risk groups. If treatment is initiated early, i.v. enalapril should be avoided; the initial dose should be low and increased progressively within 48 h with monitoring of blood pressure and renal function. Late intervention trials. The trials including selected high risk patients with treatment initiated later 48 ; after AMI and continued long term demonstrated a greater benefit obtained from the treatment with ACE-I. In the SAVE study31 2230 patients with a LVEF 40% were randomised 3 to 16 days after infarction to receive captopril or placebo. Mortality at an average follow-up of 42 months was lower in the captopril group 20% vs. 25% ; . In addition, the incidence of fatal or non-fatal major cardiovascular events was also reduced in the captopril group, including the risk for developing heart failure, hospitalisation and reinfarction. These benefits were observed in patients who received thrombolytic therapy, aspirin, or b-blockers, as well as those who did not. The TRACE study73 included 1749 patients with left ventricular systolic dysfunction LVEF 35% ; , with or without heart failure, to receive oral trandolapril or placebo 37 days after AMI. During the follow-up of 2450 months mortality was lower in the trandolapril group 34.7% vs. 42.3%; p 0: 001 ; . Trandolapril was also associated with a reduction in the risk of sudden death and progression to severe heart failure, but not with the risk of reinfarction. Long-term mortality was also investigated after a minimum of 6 years of inclusion.74 The life expectancy of patients was 4.6 years for those given placebo versus 6.2 years for those on trandolapril. Thus, the median lifetime was increased by 15.3 months or 27% in patients allocated to trandolapril during the study period, indicating that treatment during a critical period is associated with a long term benefit. In the AIRE study, 57 1986 patients with clinical evidence of heart failure at any time after AMI were randomised to receive ramipril or placebo on day three to day 10 after AMI. Follow-up was continued for a minimum of 6 months and an average of 15 months. Mortality was significantly lower in patients receiving ramipril 17% vs. 23% ; . A reduction in the combined endpoint of death, severe resistant heart failure, myocardial infarction, or stroke was also observed. This benefit was apparent as early as 30 days and was consistent across a range of subgroups. In a meta-analysis of these late trials, 53 mortality was reduced from 29.1% to 23.4% with ACE-I therapy after an average follow-up of 2.6 years. This equates to 57 fewer deaths per thousand patients treated or a NNT of 18, for! And the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions . N Engl J Med 1992; 327: 685-691. Pfeffer MA, Braunwald E, Moye LA, et al, on behalf of the SAVE Investigators. Effects of captopril on mortality in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargment Trial. N Engl J Med 1992; 327: 669-677. Gavras I: Bradykinin-mediated effects of ACE inhibition. Kidney Int. 1992; 42: 1020-1029 . 6. Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann. Intern. Med. 1992; 117: 234-242. Di Micco G, Russo B, Ducceschi V, Sarubbi B, Iacono A: Left ventricular myocardial hypertrophy: role of protooncogenes and ACE inhibition. Cardiologia 1994 Oct; 39 10 ; : 733-735 . 8. Timmermans P, Wong PC, Chin AT et al: Angiotensin II receptors and angiotensin II receptors antagonists. Pharmacol. Rev. 1993; 45: 205-251. Miura , Ideishi M, Sakai T et al: Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertension 1994; 12, 1177-1181. Tonkon M, Awan N, Niazi I, Hanley P, Baruch L, Wolf RA, Block AJ: A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Study Group. Int J Clin Pract 2000; 54: 11-14, . 11. Pitt B, Chang P, Timmermans P: Angiotensin II receptor antagonists in heart failure: rationale and design of the Evalutation of Losartan in the Elderly ELITE ; trial. Cardiovasc. Drugs Ther 1995; 9: 693-700. Pitt B, Segal R, Thiygarajan B et al.: Effects of Losartan versus Capt9pril on Mortality in patients with Symptomatic Heart Failure: Rationale Design and Baseline Characteristics of Patients in the Losartan Heart Failure Survival Study- ELITE II- Journal of Cardiac Failure; 1999; 2: 146-154. Gottlieb SS, Dickstein K, Fleck E et al: Hemodinamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993, SS: 1602-1609. 14. Packer M, Lee WH, YushakM, Medina N: Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med, 1986; 315: 847-853. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310 and cefaclor. Is captopril use associated with an altered cancer cardiovascular mortality risk compared with metoprolol use? Isabelle Lilja, University of Otago, Dunedin, New Zealand Purpose The aim of this study is to test the hypothesis that 'captopril use is associated with an altered cancer cardiovascular mortality risk compared with metoprolol'. Methodology The New Zealand Intensive Medicines Monitoring Programme IMMP ; cohorts for metoprolol and captopril assembled during monitoring of the drugs in 1977-1980 and 19811986 respectively, were used in this study. Information on mortalities, cause and date, was collected for patients by using record linkage between the IMMP database and the New Zealand Health Information Service's NZHIS ; records, as well as information from questionnaires and discharge summaries collected in a 1991 pilot study. The information was collated, cleaned and analysed. Results A statistically significant association was found between metoprolol and ovary cancer deaths, compared to captopril. No statistically significant association was found when comparing the two treatments regarding other malignancies, fatal stroke or fatal myocardial infarction MI ; . A statistically significant difference in survival time was found for the groups `MI', `cancer' and `total death'. In all these groups metoprolol patients had a longer survival time. Discussion The findings of a correlation between long-term use of metoprolol and fatal cancer of the ovary have no apparent explanation and need to be further investigated. Metoprolol has a protective effect on MI and a prolonged survival for this group was expected. This probably also accounts for part of the prolonged survival in the `total death' group. The difference found for the `cancer' group is not as easily explained, one explanation could be the age difference between the cohorts. When dealing with or referring to the Plan in terms of claim appeals or other correspondences, you will receive a more rapid response if you identify the Plan fully and accurately. To identify a plan, you need to use Marathon's employer identification number EIN ; : 25-1410539. You also need to know the Plan's official name and number. The Health Plan's official name is the Health Plan of Marathon Oil Company. It is sometimes referred to, informally, as the Marathon Health Plan, or just the Health Plan. The plan number is 504 and cefuroxime. The fda vitamin c discount prevents many drugs from reaching the market, including treatments for aids, cancer natural tamiflu and other serious illnesses, for example, captopril brand. 36. Ulick S, Blumenfeld JD, Atlas SA, Wang JZ, Vaughan ED. The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism. J Clin Endocrinol Metab 1993; 76: 8738. Stowasser M, Gordon RD. Familial hyperaldosteronism. J Steroid Biochem Mol Biol 2001; 78: 21529. Allolio B, Fassnacht M, Arlt W. Maligne Tumoren der Nebennierenrinde. Internist 2002; 43: 18695. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322: 1195201. Young WF. Primary aldosteronism. Management issues. Ann NY Acad Sci 2002; 970: 6176. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Arch Intern Med 1981; 141: 158993. Seiler L, Reincke M. Der Aldosteron-Renin-Quotient bei sekundarer Hypertonie. Herz win pressx. 43. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. J Kidney Dis 2001; 37: 699705. Baas SJ, Endert E, Fliers E, Prummel MF, Wiersinga WM. Establishment of reference values for endocrine tests. III: primary aldosteronism. Neth J Med 2003; 61: 3743. McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary aldosteronism. J Clin Endocrinol Metab 1991; 73: 9527. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol 2002; 57: 45765. Padfield PL. Prevalence and role of a raised aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice. Clin Endocrinol 2003; 59: 422426. Anonymous. Idiopathic aldosteronism a diagnostic artifact? Lancet 1979; 2: 12212. Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001; 76: 87782. Trenkel S, Seifarth C, Schobel H, Hahn EG, Hensen J. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diabetes 2002; 110: 805. Kem DC, Weinberger MH, Mayes DM, Nugent CA. Saline suppression of plasma aldosterone in hypertension. Arch Intern Med 1971; 128: 3806. Holland OB, Brown H, von Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984; 6: 71723. Agharazii M, Douville P, Grose JH, Lebel M. Capttopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 2001; 37: 14403. Opocher G, Rocco S, Carpene G, Armanini D, Mantero F. Iperaldosteronismo primitivo. Minerva Endocrinol 1995; 20: 4954. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary and citalopram. Table 5 Mean SD ; rectal mucosal flux, gastric pHi, mean femoral arterial pressure MAP ; , arterial base deficit and lactate pyruvate L P ; ratio in the two groups of patients after cardiopulmonary bypass CPB ; 20 min after end of CPB Group 1 Control ; n: 12 ; Flux arbitrary units ; pHi MAP mm Hg ; Base mmol litre91 ; L P ratio 168 82 ; 7.35 0.11 ; 44.1 12.9 ; 3.2 ; 30.3 17.7 ; Group 2 Captoprli ; n: 12 ; 131 37 ; 7.30 0.11 ; 48.8 12.9 ; 2.3 4.9 ; 36.0 26.2 ; P 0.47 0.35 min after end of CPB Group 1 Control ; n: 11 ; 256 117 ; 7.35 0.09 ; 50.6 6.2 ; 2.5 3.5 ; 22.2 5.8 ; Group 2 Capt0pril ; n: 11 ; 216 60 ; 7.25 0.11 ; 51.4 7.5 ; 4.2 4.8 ; 28.2 8.6 ; P 0.28 0.06 0.88. This drug was gsk's golden egg for many years and a lucrative business was built around its promotion and chloromycetin. It is also likely that the same carcinogenic dietary habits heavily salted, smoked and pickled food, with low consumption of fresh fruits and vegetables ; are being passed from one generation to the next. Dose of captoprilPAGE: Thank you. Okay, Robert, your chance. Should medical doctors have the right to recommend marijuana or other herbal products that are not approved by the FDA? KAMPIA: Well, you know, our, our position is that we want the maximum number of treatment options for patients. We've heard about Marinol, which is the THC pill, it was. 2 the aminoglycosides are readily available, cost-effective, generic antibiotic medications with broad-spectrum coverage and cilexetil. 19 sample of the Belgian adult population , European Journal of Clinical Nutrition, 58 1 ; , 98104. Van Antwerpen, P., Dubois, J., Gelbcke, M. et Nve, J. 2004 ; , The reactions of oxicam and sulfoanilide non steroidal antinflammatory drugs with hypochlorous acid: determination of the rate constants with an assay based on the competition with paraminobenzoic acid chlorination and identification of some oxidation products , Free Radical Research, 38 2 ; , 251-258. Van Antwerpen, P. et Nve, J. 2004 ; , In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide families , European Journal of Pharmacology, 496, 55-61. Lopes, P.A., Santos, M.C., Vicente, L., Rodrigues, M.O., Pavao, M.L., Nve, J. et ViegasCrespo, A.M. 2004 ; , Trace element status Se, Cu, Zn ; in healthy Portuguese subjects of Lisbon population. A reference study , Biological Trace Element Research, 101, 1-17. Roussel, A.M., Nve, J. et Hinninger, I. 2005 ; . Antioxydants et nutrition . Dans : Radicaux libres et stress oxydant. Aspects biologiques et pathologiques. J. Delattre, J.L. Beaudeux et D. Bonnefont-Rousselot, eds. Tec et Doc, Lavoisier, Paris, 261-280. Van Antwerpen, P., Zouaoui Boudjeltia, K., Babar, S., Legssyer, I., Moreau, P., Moguilevsky, N., Vanhaeverbeek, M., Ducobu, J. et Nve, J. 2005 ; . Thiol-containing molecules interact with the myeloperoxidase H2O2 chloride system to inhibit LDL oxidation , Biochemical Biophysical Research Communication, 337, 82-88. Van Antwerpen, P., Zouaoui Boudjeltia, K., Vaes, M., Babar, S., Madhoun, P., Moguilevsky, N., Vanhaeverbeek, M., Nve, J. et Ducobu, J. 2006 ; The pleiotropic effect of statins in haemodialysis patients is not the consequence of an inhibition of LDL oxidation by myeloperoxidase , Nephrology and Dialysis in Transplantation, 21, 2672-2674. Van Antwerpen, P., Zouaoui Boudjeltia, K., Babar, S., Legssyer, I., Moreau, P., Moguilevsky, N., Vanhaeverbeek, M., Ducobu, J. et Nve, J. 2006 ; . Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxidase in a comparative in vitro assay of angiotensin converting enzyme inhibitors , European Journal of Pharmacology, 537, 31-36. Pavo, M.L., Figueiredo, T., Santos, V., Lopes, P.A., Ferin, R., Santos, M.C., Nve, J. et Viegas-Crespo, A.M. 2006 ; . Whole blood glutathione peroxidase and erythrocyte superoxide dismutase activities, serum trace elements Se, Cu Zn ; and cardiovascular risk factors in subjects from the city of Ponta Delgada Island of San Miguel, The Azores' Archipelago, Portugal ; ", Biomarkers, 11 5 ; , 460-471. Nve, J. 2006 ; . Cadre legislatif et risques potentiels lis l'utilisation abusive des complments nutritionnels , Bulletin de la Socit Belge d'Ophthalmologie, 301, 49-52. De Burbure, C., Heiler, J.F., Nve, J., Becker, A., Albrecht, C., Borm, P., Grodmadzinska, J., Wasowicz, W., Rydzynski, K. et Bernard, A. 2007 ; , Lung permeability, antioxidant status. Michael weinstein, founder of the $45 million nonprofit aids organization aids health care foundation, the wall street journal, december 20, 1996 if the spread of hiv continues, by 2001 there could be ten billion people infected hypothetically. Captopril hcpcsFor illustrating the performance of the participating laboratories with regard to the accuracy a za-score is calculated. For the evaluation of the performance of the laboratories, the Guidelines of ISO IEC Guide 43-1 [3] and ISO DIS 13528 [17] are applied. According to these guidelines za-scores are classified as presented in Table 4. Table 4: Classification of z-scores, for example, captolril stimulation test. 61. Magnes.Trace Elem. 10 5-6 ; : 348-354, 1991. A. M. Freedman, M. M. Cassidy, and W. B. Weglicki. Magnesium-deficient myocardium demonstrates an increased susceptibility to an in vivo oxidative stress 58. Magnes.Res. 4 3-4 ; : 185-189, 1991. A. M. Freedman, M. M. Cassidy, and W. B. Weglicki. Captopril protects against myocardial injury induced by magnesium deficiency 59. Hypertension 18 2 ; : 142-147, 1991. S. J. Haleen, R. E. Weishaar, R. W. Overhiser, R. F. Bousley, J. A. Keiser, S. R. Rapundalo, and D. G. Taylor. Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathic hamster. Hemodynamic, morphological, and biochemical correlates 1. Circ Res 68 5 ; : 1302-1312, 1991. O. Hano, T. Mitsuoka, Y. Matsumoto, R. Ahmed, M. Hirata, T. Hirata, M. Mori, K. Yano, and K. Hashiba. Arrhythmogenic properties of the ventricular myocardium in cardiomyopathic Syrian hamster, BIO 14.6 strain 2. Cardiovasc.Res. 25 1 ; : 49-57, 1991. M. Horackova, A. Beresewicz, G. Rowden, and M. Wilkinson. Neurohumoral regulation of excitation-contraction coupling in ventricular myocytes from cardiomyopathic hamsters. Cardiovasc.Res. 25 12 ; : 1023-1034, 1991. S. E. Howlett, J. Bobet, and T. Gordon. Force-interval relation in normal and cardiomyopathic hamster atria 2 49. Am.J.Physiol 261 5 Pt 2 ; H1597-H1602, 1991. H. Kawaguchi, M. Shoki, H. Sano, T. Kudo, H. Sawa, H. Okamoto, Y. Sakata, and H. Yasuda. Phospholipid metabolism in cardiomyopathic hamster heart cells 9 47. Circ Res 69 4 ; : 1015-1021, 1991. J. D. McCully, J. D. Mably, M. J. Sole, and C. C. Liew. RNA transcription and translation in the hearts of normal and cardiomyopathic Syrian hamsters. Biochem.Cell Biol. 69 1 ; : 88-92, 1991. J. D. McCully, R. X. Wang, B. Kellam, M. J. Sole, and C. C. Liew. Isolation and characterization of a previously unrecognized myosin heavy chain gene present in the Syrian hamster. J.Mol.Biol. 218 4 ; : 657-665, 1991. M. Nagano, M. Kato, M. Nagai, and J. Yang. Protective effect of ACE- and kininase-inhibitor on the onset of cardiomyopathy 1. Basic Res rdiol. 86 Suppl 3: 187-195, 1991. B. H. Natelson, W. N. Tapp, S. Drastal, R. Suarez, and J. E. Ottenweller. Hamsters with coronary vasospasm are at increased risk from stress. Psychosom.Med. 53 3 ; : 322-331, 1991. E. H. Schlenker and J. A. Burbach. The dystrophic hamster: an animal model of alveolar hypoventilation 2. J.Appl.Physiol 71 5 ; : 1655-1662, 1991. V. I. Veksler, I. Murat, and R. Ventura-Clapier. Creatine kinase and mechanical and mitochondrial functions in hereditary and diabetic cardiomyopathies. Can.J.Physiol Pharmacol. 69 6 ; : 852-858, 1991 and diltiazem. Presence of food in the gastrointestinal tract reduces absorption by about 30 to 40 percent; aptopril therefore should be given one hour before meals. Based on carbon-14 labeling, average minimal absorption is approximately 75 percent. In a 24-hour period, over 95 percent of the absorbed dose is eliminated in the urine; 40 to 50 percent is unchanged drug; most of the remainder is the disulfide dimer of cwptopril and captopril-cysteine disulfide. Approximately 25 to 30 percent of the circulating drug is bound to plasma proteins. The apparent elimination half-life for total radioactivity in blood is probably less than 3 hours. An accurate determination of half-life of unchanged captopril is not, at present, possible, but it is probably less than 2 hours. In patients with renal impairment, however, retention of captopril occurs see DOSAGE AND ADMINISTRATION ; . Pharmacodynamics Administration of CAPOTEN results in a reduction of peripheral arterial resistance in hypertensive patients with either no change, or an increase, in cardiac output. There is an increase in renal blood flow following administration of CAPOTEN and glomerular filtration rate is usually unchanged. Reductions of blood pressure are usually maximal 60 to 90 minutes after oral administration of an individual dose of CAPOTEN. The duration of effect is dose related. The reduction in blood pressure may be progressive, so to achieve maximal therapeutic effects, several weeks of therapy may be required. The blood pressure lowering effects of captopril and thiazide-type diuretics are additive. In contrast, captopril and beta-blockers have a less than additive effect. Blood pressure is lowered to about the same extent in both standing and supine positions. Orthostatic effects and tachycardia are infrequent but may occur in volume-depleted patients. Abrupt withdrawal of CAPOTEN has not been associated with a rapid increase in blood pressure. In patients with heart failure, significantly decreased peripheral systemic vascular ; resistance and blood pressure afterload ; , reduced pulmonary capillary wedge pressure preload ; and pulmonary vascular resistance, increased cardiac output, and increased exercise tolerance time ETT ; have been demonstrated. These hemodynamic and clinical effects occur after the first dose and appear to persist for the duration of therapy. Placebo controlled studies of 12 weeks duration in patients who did not respond adequately to diuretics and digitalis show no tolerance to beneficial effects on ETT; open studies, with exposure up to 18 months in some cases, also indicate that ETT benefit is maintained. Clinical improvement has been observed in some patients where acute hemodynamic effects were minimal. The Survival and Ventricular Enlargement SAVE ; study was a multicenter, randomized, double-blind, placebo-controlled trial conducted in 2, 231 patients age 21-79 years ; who survived the acute phase of myocardial infarction and did not have active ischemia. Patients had left ventricular dysfunction LVD ; , defined as a resting left ventricular ejection fraction 40%, but at the time of randomization were not sufficiently symptomatic to require ACE inhibitor therapy for heart failure. About half of the patients had symptoms of heart failure in the past. Patients were given a test dose of 6.25 mg oral CAPOTEN and were randomized within 3-16 days post-infarction to receive either CAPOTEN or placebo in addition to conventional therapy. CAPOTEN was initiated at 6.25 mg or 12.5 mg tid and after two weeks titrated to a target maintenance dose of 50 mg tid. About 80% of patients were receiving the target dose at the end of the study. Patients were followed for a minimum of two years and for up to five years, with an average follow-up of 3.5 years. Baseline blood pressure was 113 70 mmHg and 112 70 mmHg for the placebo and CAPOTEN groups, respectively. Blood pressure increased slightly in both treatment groups during the study and was somewhat lower in the CAPOTEN group 119 74 vs. 125 77 mmHg at 1 yr ; Therapy with CAPOTEN improved long-term survival and clinical outcomes compared to placebo. The risk reduction for all cause mortality was 19% P 0.02 ; and for cardiovascular death was 21% P 0.014 ; . Captopril treated subjects had 22% P 0.034 ; fewer first hospitalizations for heart failure. Compared to placebo, 22% fewer patients receiving captopril developed symptoms of overt heart failure. There was no significant difference between groups in total hospitalizations for all cause 2056 placebo; 2036 captopril ; . CAPOTEN was well tolerated in the presence of other therapies such as aspirin, beta blockers, nitrates, vasodilators, calcium antagonists and diuretics. In a multicenter, double-blind, placebo controlled trial, 409. The Journal of Immunology reporting that captopril enhances T cell function in their model systems 5356 ; . The main difference between our results and those of the other groups is that we tested the effect of captopril on Ag-specific T cell proliferation and cytokine secretion, while other groups addressed this question in an Ag-nonspecific manner e.g., by Con A, LPS, and PHA responses, among others ; . We do not yet know the mechanism by which captopril affects T cell responsiveness in vivo. Some groups have suggested that differences in these effects could be due to duration of captopril exposure 57 ; , dosage 5254, 58 ; , in vitro vs in vivo administration 54 ; , and plasma levels of PGs and bradykinin 56, 59 ; , among other possibilities. We are currently addressing these hypotheses in our model system. If captopril does not directly affect T cell function, captopril may reduce inflammation and DTH by reducing recruitment of T cells to the site of antigenic stimulation or by altering the local inflammatory environment. These hypotheses are supported by our result that local injection of captopril into the DTH site reduced DTH. We are currently testing both hypotheses. Captopril has been shown to inhibit lymphocyte recruitment by decreasing chemotaxis in capillary endothelial cells 43 ; and neutrophils 44 ; . The effects of captopril on chemokines have not been addressed, but there is mounting evidence that angiotensin II affects the activities of a number of chemokines, including RANTES CCL-5 ; , monocyte chemoattractant protein-1 CCL-2 ; , and macrophage-inflammatory protein 1- CCL-3 ; reviewed in Ref. 11 ; . Captopril also reduces local inflammatory processes necessary for the induction of DTH responses, including: deposition of extravasated fibrin 17 production of proinflammatory cytokines such as TNF- 40, 41 ; , IFN- 42 ; , and IL-12 42 and dendritic cell function 45 ; . Taken together, these results show that captopril significantly reduces experimental autoimmune myocarditis. Additional mechanisms of action of captopril could involve suppression of angiotensin II levels, enhancement of bradykinin levels, or a pharmacologic effect of captopril's thiol group, among other mechanisms. Antagonists of angiotensin II receptors reduced encephalomyocarditis virus-induced myocarditis 16, 51, 60 ; . Increased bradykinin levels and activation of NO and PGs by ACE inhibitors have been implicated in providing cardiac protection via reduction of infarct size 61 ; , reduction of hypertrophy 62 ; , and reduction of collagen gene expression 63 ; . The cardioprotective effect may also be due to up-regulation of bradykinin, leading to NO synthesis 63, 64 ; , which is most likely an important molecule in autoimmune myocarditis 65 ; . Finally, the thiol group of captopril is thought to ameliorate encephalomyocarditis virus-induced myocarditis by elimination of oxygen radicals 14 ; . In conclusion, captopril ameliorates autoimmune myocarditis, as shown by its reduction of cardiac hypertrophy, inflammation, necrosis, and fibrosis. Our data suggest that captopril reduces inflammation by decreasing cell-mediated immunity, without a direct effect on T cells, but not by affecting humoral immunity. These results have direct clinical import because patients suffering from autoimmune myocarditis would benefit from captopril. Future work from our laboratory will address the mechanisms of action of captopril in decreasing inflammation, so as to increase the specificity of treatment. Ing-enzyme inhibitor in non-diabetic renal disease COOPERATE ; : A randomised controlled trial. Lancet 2003; 361: 117-24. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-convert ing enzyme inhibitors and angiotensin-II receptor antagonists: Beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253-61. Kurtz TW. Treating the metabolic syndrome: Telmisartan as a PPARgamma activator. Acta Diabetol 2005; 42: 9-16. Kintscher U, Unger T. Vascular protection in diabetes: A pharmacological view of angiotensin-II type 1 receptor blockers. Acta Diabetol 2005; 42: 26 Schupp M, Lee LD, Frost N, Umbreen S, Schmidt B, Unger T, et al. Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension 2006; 47: 586-9. Gerstein HC. Reduction of cardiovascular events and microvascular com plications in diabetes with ACE inhibitor treatment: HOPE and MICRO HOPE. Diabetes Metab Res Rev 2002; 18: 82-5. Zanella MT, Kohlmann O Jr, Ribeiro AB. Treatment of obesity hyperten sion and diabetes syndrome. Hypertension 2001; 38: 705-8. McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensinconverting enzyme inhibitors prevent diabetes and cardiovascular dis ease. J Cardiol 2003; 91: 30-7. Petroianu G, Adeghate A, Hassan MY, Saleh A, Kossanovic M, Ponery AS. Intraperitoneal exposure to captopril but not to lisinopril activates the peroxisome proliferator activated receptor PPAR ; . 8 th World Conference on Clinical Pharmacology and Therapeutics, Brisbane, Australia Abstract # PO 185 ; . Clin Experiment Pharmacol Physiol 2004; 31: 100. Adeghate E, Hasan MY, Ponery AS, Nurulain SM, Petroianu GA. Subchronic exposure to high-dose ACE inhibitor moexipril induces catalase activity in rat liver. Mol Cell Biochem 2005; 280: 159-63. da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, Wilson DW, et al. Enalapril attenuates angiotensin-II-induced atherosclerosis and vascu lar inflammation. Atherosclerosis 2005; 178: 9-17. Akbiyik F, Ray D, Bozkaya H, Demirpence E. Ligand and species-de pendent activation of PPARalpha. Cell Physiol Biochem 2004; 14: 269-76. Description of Activity Service BURN DRESS DEBRIDE-SMALL BURN DRESSING SIZE SMALL BURN DRESSING SIZED MEDM BURN DRESSING SZ LARGE BURN NET - 30 YRDS BUTOCONAZOLE NITRATE 2% CA 125 TUMOR ANTIGEN ; CALCIUM, BLOOD CHEMICAL CALCIUM, TOTAL CAMPYLOBACTER ANTIBODY CAMPYLOBACTER CULTURE CANDIDA SKIN TEST CANE THREE PRG W TIP CANE W TIP CAPREOMYCIN 1 GM INJ CAPTOPRIL 25MG TABS #10 CARBAMAZEPINE TOTAL CARBAMAZEPINE TEGRETOL CARBON DIOXIDE C02 ; CARISORPRODOL 350MG #20 CASE MGMT TOS CASE MGMT F U TO VISIT CAST APPLIC-HAND&FOREARM CAST APPLIC-LONG ARM CAST APPLIC-SHORT ARM CAST APPLIC-SHORT LEG CAST APPLIC-SHRT LEG WALK CAST MATERIAL FIBER CAST SPLINT PROCEDURE CAST SHOE CAST WINDOWING CATHETER URIN KIT FEMALE CATHETER URIN KIT PEDS 5F CATHETER URIN ROBINSON 16F CATHETERIZE URETH SIMPLE CAUERY W SILVER NITRATE CBC-COMPL BLD COUNT W DIF CBC-CMP BLD CT W DIF STAT CD INTERM VST 12-18M EST CDP CASE MANAGEMENT CEA-CARCINOEMBRYONIC ANTG CEFAZOLIN 500 MG 1GM INJ CEPHALEXIN 500MG #30 CEPHALEXIN KEFLEX 500MG #40 CERV BRIEF VISIT 6 MN EST CERV BRIEF VISIT 6 MN NEW CERV COMPREHENS VISIT EST CERV COMPREHENS VISIT NEW CERV EXTEND VST 18-30 EST CERV EXTEND VST 18-30 NEW CERV INTERM VST 12-18 NEW CERV INTERM VST 12-81 EST CERV LIMITED VST 6-12 EST CERV LIMITED VST 6-12 NEW CERV MINIML SVC VISIT EST CERVICAL BIOPSY S ; CERVICAL CAP CERVICAL COLLAR SOFT CERVICAL SPINE-3 VIEWS Current Fee: $47.00 $26.00 $42.00 $63.00 $0.65 $11.99 $26.46 $8.00 $6.56 $18.20 $13.80 $15.35 $43.13 $25.00 $63.00 $4.00 $18.52 $38.00 $6.25 $6.65 $57.50 $95.91 $106.61 $95.05 $98.05 $96.34 $24.00 $47.00 $70.00 $46.00 $100.00 $64.00 $48.00 $75.00 $38.00 $10.75 $17.13 $63.25 $57.50 $29.00 $28.00 $12.45 $12.00 $34.50 $36.80 $132.25 $134.55 $84.00 $106.75 $86.00 $63.25 $55.20 $57.50 $26.45 $70.00 $40.00 $28.00 $52.90 Proposed Fee: $47.00 $26.00 $42.00 $63.00 $0.65 $11.99 $26.46 $8.00 $6.56 $18.20 $13.80 $15.35 $43.13 $25.00 $63.00 $4.00 $18.52 $38.00 $6.25 $6.65 $57.50 $95.91 $106.61 $95.05 $98.05 $96.34 $24.00 $47.00 $70.00 $46.00 $100.00 $64.00 $48.00 $75.00 $38.00 $10.75 $17.13 $63.25 $57.50 $29.00 $28.00 $12.45 $12.00 $34.50 $36.80 $132.25 $134.55 $84.00 $106.75 $86.00 $63.25 $55.20 $57.50 $26.45 $70.00 $40.00 $28.00 $52.90. This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: high potassium blood levels, severe kidney disease e.g., chronic kidney failure, inability to make urine ; , untreated underactive adrenal gland, sudden loss of body fluids acute dehydration ; , severe conditions of tissue breakdown e.g., severe burns, traumatic injury ; . Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney problems, certain types of heart disease e.g., atrioventricular block ; , esophagus stomach intestinal problems e.g., stomach ulcers, slowed movement, blockage ; . Kidney function declines as you grow older. This medication is removed by the kidneys. Therefore, elderly people may be more sensitive to the effects of this drug. This medication should be used only when clearly needed during pregnancy. Discuss the risks and benefits with your doctor. It is not known whether this drug passes into breast milk. Consult your doctor before breast-feeding. DRUG INTERACTIONS: Your healthcare professionals e.g., doctor or pharmacist ; may already be aware of any possible drug interactions and may be monitoring you for it. Do not start, stop or change the dosage of any medicine before checking with them first. Before taking potassium supplements, check with your doctor if you are taking other medications products that may also increase the potassium level in your blood. A potassium level in the blood that is too high may cause serious side effects. Follow your doctor's instructions carefully and continue medications for your condition as directed. Keep all medical laboratory appointments so your doctor can monitor your potassium levels. Consult with your doctor if you are taking any of the following: ACE inhibitors e.g., captopril, lisinopril ; , angiotensin receptor blockers ARBs such as candesartan, losartan ; , eplerenone, potassium-sparing "water pills" diuretics such as amiloride, spironolactone, triamterene ; , salt substitutes containing potassium. Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription herbal products you may use, especially of: digoxin, drospirenone, "water pills" diuretics such as furosemide, hydrochlorothiazide ; . Also tell your doctor or pharmacist if you take medications that may slow down the movement of potassium capsules tablets in your digestive system, possibly increasing the risk of side effects. These drugs include: anticholinergic drugs e.g., atropine, scopolamine ; , certain antihistamines e.g., diphenhydramine ; , antispasmodic drugs e.g., dicyclomine, hyoscyamine ; , certain anti-Parkinson's drugs e.g., benztropine, trihexyphenidyl ; , belladonna alkaloids, bladder control drugs e.g., oxybutynin, tolterodine ; . NOTES: Do not share this medication with others. Laboratory and or medical tests e.g., potassium blood level, kidney function tests ; should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details. Eat a well-balanced diet. Foods high in potassium include: bananas, oranges, watermelon, cantaloupe, raisins, dates, prunes, avocados, apricots, beans, broccoli, leafy green vegetables, spinach, potatoes, lentils, fish, chicken, turkey, ham, beef, and milk. Consult your doctor or pharmacist regarding your specific dietary plan. OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US national poison hotline at 1-800-222-1222. Canadian residents should call their local poison control center directly. Symptoms of overdose may include irregular heartbeat, muscle weakness, confusion, numbness tingling of the hands feet, chest pain. Drug Captopril Enalapril Lisinopril Quinapril Perindopril Ramipril Trandolapril Starting dose mg ; 6.25 2.5 Maintenance dose mg ; 25-50 10 * 5-20 5-10 * 4 2.5-5 * 2-4. Did not examine a number of other factors that may affect HbA1c, including drug therapy, diet, body weight, and physical activity level in our population, but assume any influence of these is small based on comparison with the small changes in the nonstudy diabetic population during the same interval. Finally, the cohort on which we focused our attention represented roughly a third of the total population receiving strips. As such, it could be argued that they may have represented a more adherent or healthier population, and an adverse effect of strip use reduction more apparent in the noncohort individuals might be overlooked. Our data indicate the following: the cohort patients were not overtly different from the other patients in overall clinical characteristics; the cohort patients were not treated more aggressively than the other patients; and the cohort patients did not keep more appointments than the other patients. As such, we think any bias from this "nonignorable" missing data is insignificant. Both the apparent benefit of SMBG in our patients and the lack of impact of a modest reduction in strip use might reflect highly focused subspecialty care. However, most of our diabetic patients are seen by general internists, with only about one third receiving subspecialty diabetes input.6, 9 It is therefore unlikely that direct subspecialty care contributed in a major way to our findings. It is probable that the observed benefit of SMBG, as well as the stability of HbA1c, reflect a systematic approach to diabetes care emphasizing education and involvement of primary providers in diabetes management. However, it is also likely that other risk factors for poor glycemic control segregate with nonuse of BG strips, and therefore these data are not definitive. Although the decrease in strip use from 1.36 to 0.74 strip per day may seem small, and somewhat artificial because patients do not use fractional strips, we did report a 45% reduction in strip use in the patients studied. Given that VANCHCS spent almost half a million dollars on testing supplies in 1997, this reduction in strip use potentially represents a large institutional financial benefit. Although some patients were not studied eg, those on insulin ; , it is clear that, for certain patients, this strip use policy could be safely implemented. Our study has design limitations as well. A more rigorous design would have been a randomized study in which individuals were randomized to a nochange group or a decrease in frequency of SMBG testing and then a comparison of HbA1c levels between groups. Although our study was not randomized, we believe that, based on comparisons before and after, our conclusion is valid that a decrease in the frequency of SMBG testing does not result in a deterioration of HbA1c levels. Pharmacists played an important role in this program, including education not only about SMBG, but also about medication and diabetes in general. In addition, pharmacists, faced with budgetary pressures, identified a cost-savings strategy that was safe, practical, and readily accepted by patients and providers. Van Veldhuizen-Scott and colleagues32 found that pharmacists' counseling significantly improved patient understanding of diabetes medications, increased patient knowledge about blood glucose monitoring, and made a positive difference in perceptions and attitudes toward diabetes and communication with the pharmacist. Coast-Senior and coworkers33 determined that pharmacists providing diabetes education, medication counseling, monitoring, and insulin initiation or adjustments had a positive impact on glycemic control in patients with type 2 diabetes requiring insulin. With monthly refills of prescribed medications, pharmacists have the opportunity to interact with patients with diabetes more often than most members of the healthcare team. As numbers of patients with diabetes increase and healthcare dollars become more limited, we must seek opportunities to reduce the cost of diabetes care while maintaining or improving the quality of that care. This program worked well in a setting of overall stability with patients and providers already educated about the goals of diabetes care. Flexibility is critical to accommodate those who require more intensive monitoring, with both long-term and short-term glycemic goals clearly defined. In summary, we demonstrated that a multidisciplinary approach to chronic disease management, requiring input and cooperation from providers, nurse educators, and pharmacists, in a suitable patient population, resulted in significant cost savings without compromising patient care. Although we were able to substantially decrease the frequency of SMBG, the ideal frequency of this testing remains to be determined.
|
Hosted by T35 Free Web Hosting. Sunglasses Sale - Casino Reviews - Los Angeles VW - Center for Addiction - Online Degree - Cheap Domain - Gucci Sneakers - Bianchi